Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

115.69 -0.01 (-0.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 Next >
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
Via AB Newswire
Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
From Alpine Immune Sciences, Inc. and Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
From Horizon Therapeutics plc
Via Business Wire
Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
From Horizon Therapeutics plc
Via Business Wire
New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
From Horizon Therapeutics plc
Via Business Wire
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
From Horizon Therapeutics plc
Via Business Wire
Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
From Horizon Therapeutics plc
Via Business Wire
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
From Horizon Therapeutics plc
Via Business Wire
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.